A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma

Clinical Cancer Research

Volumn 14, Issue 7, 2008, Pages 2154-2160

  Wang, Michael ^a   Zhang, Liang ^a   Han, Xiaohong ^a,b   Yang, Jing ^a   Qian, Jianfei ^a   Hong, Sungyoul ^a   Lin, Pei ^a   Shi, Yuankai ^b   Romaguera, Jorge ^a   Kwak, Larry W ^a   Yi, Qing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATIPRIMOD; BETA 2 MICROGLOBULIN; CD20 ANTIBODY; CYCLIN D1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; ENGRAFTMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; TUMOR GROWTH;

AGED; ANIMALS; BETA 2-MICROGLOBULIN; BONE AND BONES; BONE TRANSPLANTATION; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION;

EID: 42249089099     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4409     Document Type: Article

References (27)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
2. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89:2067-78.
3. Williams ME, Densmore JJ. Biology and therapy of mantle cell lymphoma. Curr Opin Oncol 2005;17:425-31.
4. Kurtin PJ. Mantle cell lymphoma. Adv Anat Pathol 1998;5:376-98.
5. Yatabe Y, Suzuki R, Matsuno Y, et al. Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases. Pathol Int 2001;51:747-61.
6. Salar A, Juanpere N, Bellosillo B, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 2006;30:1274-80.
7. Wang M, Zhang L, Han X, et al. Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. Blood 2007;109:5455-62.
8. Carlo-Stella C, Di Nicola M, Turco MC, et al. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2006;66:1799-808.
9. Ford RJ, Shen L, Lin-Lee YC, et al. Development of a murine model for blastoid variant mantle-cell lymphoma. Blood 2007;109:4899-906.
10. Smith MR, Joshi I, Jin F, Al-Saleem T. Murine model for mantle cell lymphoma. Leukemia 2006;20:891-3.
11. Bryant J, Pham L, Yoshimura L, et al. Development of intermediate-grade (mantle cell) and low-grade (small lymphocytic and marginal zone) human non-Hodgkin's lymphomas xenotransplanted in severe combined immunodeficiency mouse models. Lab Invest 2000;80:557-73.
12. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998;92:2908-13.
13. McCune JM, Namikawa R, Kaneshima H, et al. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988;241:1632-9.
14. Chen BP, Galy A, Kyoizumi S, et al. Engraftment of human hematopoietic precursor cells with secondary transfer potential in SCID-hu mice. Blood 1994;84:2497-505.
15. Kyoizumi S, Baum CM, Kaneshima H, et al. Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood 1992;79:1704-11.
16. Sandhu JS, Clark BR, Boynton EL, et al. Human hematopoiesis in SCID mice implanted with human adult cancellous bone. Blood 1996;88:1973-82.
17. Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997;90:754-65.
18. Namikawa R, Ueda R, Kyoizumi S. Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice. Blood 1993;82:2526-36.
19. Hamasaki M, Hideshima T, Tassone P, et al. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood 2005;105:4470-6.
20. Faderl S, Ferrajoli A, Harris D, et al. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res 2007;31:91-5.
21. Kaneshima H, Baum C, Chen B, et al. Today's SCID-hu mouse. Nature 1990;348:561-2.
22. McCune JM. Development and applications of the SCID-hu mouse model. Semin Immunol 1996;8:187-96.
23. Carballido JM, Namikawa R, Carballido-Perrig N, et al. Generation of primary antigen-specific human T- and B-cell responses in immunocompetent SCID-hu mice. Nat Med 2000;6:103-6.
24. Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 2004;64:2016-23.
25. Cohen PL, Kurtin PJ, Donovan KA, Hanson CA. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol 1998;101:302-10.
26. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-23.
27. Fisher RI, Dahlberg S, Nathwani BN, et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995;85:1075-82.